BCR and neoplasm: SY-1530 inhibits the phosphorylation of BTK and the activity of BTK downstream kinases such as PLCγ2 and ERK, thus blocking the BCR signaling pathway and suppressing tumor growth in B-cell malignancies (Figure 6C).